Mehmet Taylan PEKÖZ
(Çukurova Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, Adana. Türkiye)
Hacer BOZDEMİR
(Çukurova Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, Adana. Türkiye)
Ahmet Yusuf ERTÜRK
(Muş Devlet Hastanesi Nöroloji Anabilim Dalı, Muş. Türkiye)
Ümit SATILMIŞ
(Elbistan Devlet Hastanesi, Nöroloji Anabilim Dalı, Kahramanmaraş. Türkiye)
Kezban ASLAN
(Çukurova Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, Adana. Türkiye)
Yıl: 2021Cilt: 27Sayı: 3ISSN: 1300-7157Sayfa Aralığı: 150 - 154İngilizce

0 0
The Effect of Lacosamide Polytherapy on Seizure Prognosis in Focal Epilepsies
Objectives: What is expected from anti-epileptic treatment is low side effects and drug-drug interactions as well as high efficacy. In this study, the efficacy of lacosamide in polytherapy and its effect on prognosis were evaluated. Methods: Seventy-seven patients with focal epilepsy who were followed up for at least 1 year and using lacosamide were included in the study. The antiepileptic drugs they use, the side effects of the drugs, neuroimaging and electrophysiological examinations were evaluated. Results: A total of 77 patients, including 35 women (44.9%) and 42 men (55.1%), were included in the study. The mean age was 33.9±10.6 (min: 19 max: 67). Average age of seizure onset was 12.6±10.7, and none of the patients were using Lacosamide (LKS) as monotherapy. Although only 3 patients were receiving dual therapy, the remaining 74 patients were receiving 3 or more antiepileptic treatments. While 33 of the patients (42.9%) had a decrease in the frequency of seizures after LKS treatment. Conclusion: Although the percentage of efficacy was obtained as low according to literature information, lacosamide is effective in resistant focal epilepsies with an efficiency of 42.9%. Especially in patients who use drugs other than antiepileptic drugs due to comorbid diseases, the absence of drug-drug interaction and the absence of serious side effects that require termination of treatment may be an indication that it can be used safely.
DergiAraştırma MakalesiErişime Açık
  • 1. Kwan P, Brodie M. Early identification of refractory epilepsy. N Engl J Med 2000;(342):314–19.
  • 2. Steve S Chung. Newly available treatments for epilepsy: review of clinical studies of lacosamide, ezogabine, perampanel and eslicarbazepine acetate. Clin Invest (Lond) 2014;4(9):839−46.
  • 3. Thomas D, Scharfenecker U, Nickel B, Doty P, Cawello W, Horstmann R. Low potential for drug–drug interaction of lacosamide. Epilepsia 2006;47:200.
  • 4. Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today (Barc) 2008;44(1):35−40.
  • 5. Chung SS. New treatment option for partial-onset seizures: efficacy and safety of lacosamide. Ther Adv Neurol Disord 2010;3(2):77−83.
  • 6. Vossler DG, Knake S, O’Brien TJ, Watanabe M, Brock M, Steiniger-Brach B, et al; SP0982 co-investigators. Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial. J Neurol Neurosurg Psychiatry 2020;91(10):1067−75.
  • 7. Li J, Sun M, Wang X. The adverse-effect profile of lacosamide. Expert Opin Drug Saf 2020;19(2):131−8.
  • 8. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):512−21.
  • 9. Chu-Shore CJ, Thiele EA. Dirençli fokal epilepside lakozamid ek tedavisi: 3. basamak merkez tecrübemiz. Epilepsi 2010;17(4):214−23.
  • 10. Algın Dİ, Erdinç OO, Akdağ G. Fokal nöbetli hastalarda lakosamid ek tedavisi ile ilgili klinik deneyimler. epilepsi 2017;23(2):57−62.
  • 11. Villanueva V, López FJ, Serratosa JM, González-Giraldez B, Campos D, Molins A, et al. Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide. Epilepsy Behav 2013;29(2):349−56.
  • 12. Neal A, D’Souza W, Hepworth G, Lawn N, Cook M, Nikpour A. Efficacy and tolerability of adjuvant lacosamide: The role of clinical characteristics and mechanisms of action of concomitant AEDs. Epilepsy Behav 2018;80:25–32.
  • 13. Gürses AA, Genç E, Genç BO. Lacosamide add-on treatment in refractory focal epilepsy: the experience of a single tertiary center. Epilepsia 2020;26(2):88−93.
  • 14. Koç G, Bek S, Karadaş Ö, Eroğlu E, Gökçil Z. Fokal başlangıçlı epilepside lakozamidin ek tedavideki yeri. Epilepsi 2017;23(3):103– 8.
  • 15. Arabi M, Alsaadi T, Nasreddine W, Al-Hashel J, Dirani M, Beydoun A. Efficacy and tolerability of treatment with lacosamide: Postmarketing experience from the Middle East region. Epilepsy Behav 2018;84:118−21.
  • 16. Eren F, Dirican AC, Gül G, Tekin B, Atakli D, Baybaş S. Fokal başlangıçlı nöbetleri olan dirençli epilepsi hastalarında lakozamid ekleme tedavisinin kısa dönem sonuçları. Epilepsi 2021;27(1):47−51.
  • 17. Delcker A, Wilhelm H, Timmann D, Diener HC. Side effects from increased doses of carbamazepine on neuropsychological and posturographic parameters of humans. Eur Neuropsychopharmacol 1997;7(3):213−8.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.